FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1841572063> ?p ?o ?g. }

• W1841572063 endingPage "246" @default.
• W1841572063 startingPage "1" @default.
• W1841572063 abstract "Background Chronic obstructive pulmonary disease (COPD) is a chronic progressive lung disease characterised by non-reversible airflow obstruction. Exacerbations are a key cause of morbidity and mortality and place a considerable burden on health-care systems. While there is evidence that patients benefit from non-invasive ventilation (NIV) in hospital during an acute exacerbation, evidence supporting home use for more stable COPD patients is limited. In the UK, domiciliary NIV is considered on health economic grounds in patients after three hospital admissions for acute hypercapnic respiratory failure. Objective To assess the clinical effectiveness and cost-effectiveness of domiciliary NIV by systematic review and economic evaluation. Data sources Bibliographic databases, conference proceedings and ongoing trial registries up to September 2014. Methods Standard systematic review methods were used for identifying relevant clinical effectiveness and cost-effectiveness studies assessing NIV compared with usual care or comparing different types of NIV. Risk of bias was assessed using Cochrane guidelines and relevant economic checklists. Results for primary effectiveness outcomes (mortality, hospitalisations, exacerbations and quality of life) were presented, where possible, in forest plots. A speculative Markov decision model was developed to compare the cost-effectiveness of domiciliary NIV with usual care from a UK perspective for post-hospital and more stable populations separately. Results Thirty-one controlled effectiveness studies were identified, which report a variety of outcomes. For stable patients, a modest volume of evidence found no benefit from domiciliary NIV for survival and some non-significant beneficial trends for hospitalisations and quality of life. For post-hospital patients, no benefit from NIV could be shown in terms of survival (from randomised controlled trials) and findings for hospital admissions were inconsistent and based on limited evidence. No conclusions could be drawn regarding potential benefit from different types of NIV. No cost-effectiveness studies of domiciliary NIV were identified. Economic modelling suggested that NIV may be cost-effective in a stable population at a threshold of £30,000 per quality-adjusted life-year (QALY) gained (incremental cost-effectiveness ratio £28,162), but this is associated with uncertainty. In the case of the post-hospital population, results for three separate base cases ranged from usual care dominating to NIV being cost-effective, with an incremental cost-effectiveness ratio of less than £10,000 per QALY gained. All estimates were sensitive to effectiveness estimates, length of benefit from NIV (currently unknown) and some costs. Modelling suggested that reductions in the rate of hospital admissions per patient per year of 24% and 15% in the stable and post-hospital populations, respectively, are required for NIV to be cost-effective. Limitations Evidence on key clinical outcomes remains limited, particularly quality-of-life and long-term (> 2 years) effects. Economic modelling should be viewed as speculative because of uncertainty around effect estimates, baseline risks, length of benefit of NIV and limited quality-of-life/utility data. Conclusions The cost-effectiveness of domiciliary NIV remains uncertain and the findings in this report are sensitive to emergent data. Further evidence is required to identify patients most likely to benefit from domiciliary NIV and to establish optimum time points for starting NIV and equipment settings. Future work recommendations The results from this report will need to be re-examined in the light of any new trial results, particularly in terms of reducing the uncertainty in the economic model. Any new randomised controlled trials should consider including a sham non-invasive ventilation arm and/or a higher- and lower-pressure arm. Individual participant data analyses may help to determine whether or not there are any patient characteristics or equipment settings that are predictive of a benefit of NIV and to establish optimum time points for starting (and potentially discounting) NIV. Study registration This study is registered as PROSPERO CRD42012003286. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W1841572063 created "2016-06-24" @default.
• W1841572063 creator A5015107938 @default.
• W1841572063 creator A5026936723 @default.
• W1841572063 creator A5028714635 @default.
• W1841572063 creator A5037797777 @default.
• W1841572063 creator A5041409126 @default.
• W1841572063 creator A5047963230 @default.
• W1841572063 creator A5049709428 @default.
• W1841572063 creator A5051537242 @default.
• W1841572063 creator A5063027770 @default.
• W1841572063 creator A5068270981 @default.
• W1841572063 creator A5068920522 @default.
• W1841572063 date "2015-10-01" @default.
• W1841572063 modified "2023-10-11" @default.
• W1841572063 title "The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation" @default.
• W1841572063 cites W1514781929 @default.
• W1841572063 cites W1518926765 @default.
• W1841572063 cites W1526181706 @default.
• W1841572063 cites W1528964789 @default.
• W1841572063 cites W1549630912 @default.
• W1841572063 cites W1555991566 @default.
• W1841572063 cites W1606382408 @default.
• W1841572063 cites W166652223 @default.
• W1841572063 cites W1828314202 @default.
• W1841572063 cites W1849863957 @default.
• W1841572063 cites W1936272977 @default.
• W1841572063 cites W1964587183 @default.
• W1841572063 cites W1965981085 @default.
• W1841572063 cites W1969350669 @default.
• W1841572063 cites W1973121100 @default.
• W1841572063 cites W1973336797 @default.
• W1841572063 cites W1973742535 @default.
• W1841572063 cites W1974682028 @default.
• W1841572063 cites W1974704643 @default.
• W1841572063 cites W1975995061 @default.
• W1841572063 cites W1981204838 @default.
• W1841572063 cites W1985857023 @default.
• W1841572063 cites W1987963682 @default.
• W1841572063 cites W1988645485 @default.
• W1841572063 cites W1989413449 @default.
• W1841572063 cites W1991297890 @default.
• W1841572063 cites W1991319128 @default.
• W1841572063 cites W1992927517 @default.
• W1841572063 cites W1994439155 @default.
• W1841572063 cites W1997004974 @default.
• W1841572063 cites W1998627865 @default.
• W1841572063 cites W1999541457 @default.
• W1841572063 cites W2001798576 @default.
• W1841572063 cites W2002726093 @default.
• W1841572063 cites W2003597948 @default.
• W1841572063 cites W2007789952 @default.
• W1841572063 cites W2009285462 @default.
• W1841572063 cites W2010368883 @default.
• W1841572063 cites W2012967446 @default.
• W1841572063 cites W2014744551 @default.
• W1841572063 cites W2014822737 @default.
• W1841572063 cites W2015332210 @default.
• W1841572063 cites W2019687895 @default.
• W1841572063 cites W2024037973 @default.
• W1841572063 cites W2028618548 @default.
• W1841572063 cites W2031927056 @default.
• W1841572063 cites W2033112249 @default.
• W1841572063 cites W2036579035 @default.
• W1841572063 cites W2037790667 @default.
• W1841572063 cites W2044620587 @default.
• W1841572063 cites W2045340501 @default.
• W1841572063 cites W2046081129 @default.
• W1841572063 cites W2047571479 @default.
• W1841572063 cites W2049273966 @default.
• W1841572063 cites W2050877844 @default.
• W1841572063 cites W2056309129 @default.
• W1841572063 cites W2060513754 @default.
• W1841572063 cites W2062644114 @default.
• W1841572063 cites W2065677399 @default.
• W1841572063 cites W2067470530 @default.
• W1841572063 cites W2068137923 @default.
• W1841572063 cites W2069485242 @default.
• W1841572063 cites W2073673004 @default.
• W1841572063 cites W2075120583 @default.
• W1841572063 cites W2080784345 @default.
• W1841572063 cites W2081714851 @default.
• W1841572063 cites W2082937009 @default.
• W1841572063 cites W2083436606 @default.
• W1841572063 cites W2087010189 @default.
• W1841572063 cites W2090752240 @default.
• W1841572063 cites W2092692261 @default.
• W1841572063 cites W2095261002 @default.
• W1841572063 cites W2096506125 @default.
• W1841572063 cites W2097223780 @default.
• W1841572063 cites W2098186317 @default.
• W1841572063 cites W2098643589 @default.
• W1841572063 cites W2099304231 @default.
• W1841572063 cites W2099702934 @default.
• W1841572063 cites W2100843875 @default.
• W1841572063 cites W2101787490 @default.
• W1841572063 cites W2101918266 @default.
• W1841572063 cites W2102516680 @default.

• next